

THERAVANCE INC  
Form 8-K  
October 28, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant**  
**to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **October 28, 2014**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**000-30319**  
(Commission File Number)

**94-3265960**  
(I.R.S. Employer Identification Number)

Edgar Filing: THERAVANCE INC - Form 8-K

**951 Gateway Boulevard  
South San Francisco, California 94080  
(650) 238-9600**

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On October 28, 2014 at CHEST 2014 in Austin, Texas, GlaxoSmithKline plc (GSK) presented data from two Phase 3 studies evaluating the efficacy and safety of the open triple therapy, the once-daily umeclidinium (UMEC), a long-acting muscarinic antagonist, added to fluticasone furoate/vilanterol (FF/VI), in chronic obstructive pulmonary disease. FF/VI is a once-daily combination of a long-acting beta2 agonist (LABA) and inhaled corticosteroid. FF/VI has been developed under the 2002 LABA collaboration between Glaxo Group Limited and Theravance, Inc. The slide presentation is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit</b>	<b>Description</b>
Exhibit 99.1	Efficacy and Safety of Once-Daily Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease: Results of Two Replicate Randomized 12-Week Studies

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Date: October 28, 2014

By:

**/s/ Michael W. Aguiar**  
**Michael W. Aguiar**  
**Chief Executive Officer**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Efficacy and Safety of Once-Daily Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease: Results of Two Replicate Randomized 12-Week Studies